Animalcare Group plc (LSE:ANCR) reported a strong trading performance for 2025, with revenue increasing by around 20% to approximately £89.1m and underlying EBITDA rising by about 50%. Growth was supported by the successful acquisition and integration of Randlab, double-digit sales growth from flagship companion animal brands such as Daxocox, and a significantly expanded equine portfolio, which now contributes close to a quarter of total group revenue.
The company highlighted its resilient balance sheet and healthy cash generation, alongside continued progress across its three strategic priorities of organic growth, mergers and acquisitions, and new product development. Animalcare also pointed to a strengthened R&D pipeline, comprising five core projects, including the VHH NGF antibody programme and a newly licensed equine biologics technology. Management said these initiatives position the group for faster and more sustainable growth, with plans to outline its strategy in more detail at a capital markets event scheduled for March.
Looking ahead, Animalcare’s outlook reflects strong financial foundations and encouraging corporate developments, although valuation metrics are less supportive given a negative P/E ratio. Technical indicators imply moderate upside potential, while the company’s strategic execution and visible director confidence are viewed as key positives.
More about Animalcare
Animalcare Group plc is a UK AIM-listed international veterinary sales and marketing organisation focused on animal health. The group operates across seven European countries as well as Australia and New Zealand, and exports products to around 40 markets globally. It specialises in bringing innovative veterinary medicines and solutions to market for companion, production, and equine animals through internal development, partnerships, and acquisitions.
Leave a Reply